Q-omics provides the consensus-scored MAD2L1P1 profile across patient tissues and cancer cell-line models. MAD2L1P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, MAD2L1P1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, MAD2L1P1 RNA expression shows 17,887 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight OV, COAD, and GBM as cancer lineages where MAD2L1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAD2L1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAD2L1P1 survival associations across molecular data types. MAD2L1P1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAD2L1P1 RNA expression–survival associations across cancer types. High MAD2L1P1 expression shows unfavorable associations in ACC, but favorable associations in OV, LAML, PAAD, GBM and LUSC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify OV as the clearest survival context for MAD2L1P1 RNA expression.
This table summarizes MAD2L1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MAD2L1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAD2L1P1 shows lower tumor expression in KICH and higher tumor expression in COAD, UCEC, BRCA, LIHC and STAD. The COAD box plot shows higher MAD2L1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.340, t-test p < 0.001).
This table shows molecular features associated with MAD2L1P1 in patient tissues and cancer cell lines. In patient samples, MAD2L1P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
